Faruqi & Faruqi Investigates Replimune Securities Class Action.

Faruqi & Faruqi LLP is investigating potential claims against Replimune Group, Inc. for securities fraud. The investigation concerns investors who purchased or acquired securities between November 22, 2024 and July 21, 2025. Investors are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their options. The deadline to seek the role of lead plaintiff is September 22, 2025.

Replimune Group, Inc. (NASDAQ: REPL) is currently facing a securities fraud lawsuit, with two prominent law firms, Block & Leviton LLP and Faruqi & Faruqi, LLP, investigating potential claims on behalf of investors who purchased or acquired securities between November 22, 2024, and July 21, 2025 [1][2][3].

The lawsuit alleges that Replimune Group, Inc. made false and/or misleading statements regarding the prospects of their IGNYTE trial, which resulted in the U.S. Food and Drug Administration (FDA) deeming the trial inadequate and not well-controlled. This led to a significant drop in the company's stock price, with shares falling over 73% during intraday trading on July 22, 2025 [2][3].

Investors who have suffered losses due to this situation are encouraged to contact the law firms to discuss their legal rights. The deadline to seek the role of lead plaintiff in the class action lawsuit is September 22, 2025. Investors should note that they can remain absent class members if they choose not to participate [1][2][3].

Block & Leviton LLP and Faruqi & Faruqi, LLP have both recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of their clients through active litigation in the federal courts across the country [1][2][3].

For more information, investors can visit the respective law firms' websites or contact them directly. Block & Leviton LLP can be reached at (888) 256-2510 or shareholders@blockleviton.com, while Faruqi & Faruqi, LLP can be reached at 877-247-4292 or 212-983-9330 (Ext. 1310) [1][2][3].

References:
[1] https://www.globenewswire.com/news-release/2025/08/05/3127689/0/en/REPL-DEADLINE-Replimune-Group-Investors-Should-Contact-Block-Leviton-By-September-22nd-To-Join-Securities-Fraud-Lawsuit.html
[2] https://www.prnewswire.com/news-releases/faruqi--faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025---repl-302525489.html
[3] https://www.newsfilecorp.com/release/261173/SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Replimune